Association of the ANRS-12126 Male Circumcision Project with HIV Levels among Men in a South African Township: Evaluation of Effectiveness using Cross-sectional Surveys

English version České info

Background:
Randomized controlled trials have shown that voluntary medical male circumcision (VMMC) reduces HIV infection by 50% to 60% in sub-Saharan African populations; however, little is known about the population-level effect of adult male circumcision (MC) as an HIV prevention method. We assessed the effectiveness of VMMC roll-out on the levels of HIV in the South African township of Orange Farm where the first randomized controlled trial (RCT) to test the effect of VMMC on HIV acquisition was conducted in 2002–2005.

Methods and Findings:
The Bophelo Pele project is a community-based campaign against HIV, which includes the roll-out of free VMMC. A baseline cross-sectional biomedical survey was conducted in 2007–2008 among a random sample of 1,998 men aged 15 to 49 (survey response rate 80.7%). In 2010–2011, we conducted a follow-up random survey among 3,338 men aged 15 to 49 (survey response rate 79.6%) to evaluate the project. Participants were interviewed, blood samples were collected and tested for HIV and recent HIV infection (using the BED HIV incidence assay), and MC status was assessed through a clinical examination. Data were analyzed using multivariate and propensity statistical methods.

Owing to the VMMCs performed in the context of the RCT and the Bophelo Pele project, the prevalence rate of adult MC increased from 0.12 (95% CI 0.10–0.14) to 0.53 (95% CI 0.51–0.55). Without these VMMCs, the HIV prevalence rate in 2010–2011 would have been 19% (95% CI 12%–26%) higher (0.147 instead of 0.123).

When comparing circumcised and uncircumcised men, no association of MC status with sexual behavior was detected. Among circumcised and uncircumcised men, the proportion consistently using condoms with non-spousal partners in the past 12 months was 44.0% (95% CI 41.7%–46.5%) versus 45.4% (95% CI 42.2%–48.6%) with weighted prevalence rate ratio (wPRR) = 0.94 (95% CI 0.85–1.03). The proportion having two or more non-spousal partners was 50.4% (95% CI 47.9%–52.9%) versus 44.2% (95% CI 41.3%–46.9%) with wPRR = 1.03 (95% CI 0.95–1.10).

We found a reduction of BED-estimated HIV incidence rate ranging from 57% (95% CI 29%–76%) to 61% (95% CI 14%–83%) among circumcised men in comparison with uncircumcised men.

Conclusions:
Findings suggest that the roll-out of VMMC in Orange Farm is associated with a significant reduction of HIV levels in the community. The main limitation of the study is that it was not randomized and cannot prove a causal association. The roll-out of VMMC among adults in sub-Saharan Africa should be an international priority and needs to be accelerated to effectively combat the spread of HIV.

Please see later in the article for the Editors' Summary

Vyšlo v časopise: Association of the ANRS-12126 Male Circumcision Project with HIV Levels among Men in a South African Township: Evaluation of Effectiveness using Cross-sectional Surveys. PLoS Med 10(9): e32767. doi:10.1371/journal.pmed.1001509
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pmed.1001509

Souhrn

Zdroje

1. UNAIDS (2012) UNAIDS Report on the global AIDS epidemic. Geneva: WHO.

2. AuvertB, TaljaardD, LagardeE, Sobngwi-TambekouJ, SittaR, et al. (2005) Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med 2: e298 doi:10.1371/journal.pmed.0020298

3. BaileyRC, MosesS, ParkerCB, AgotK, MacleanI, et al. (2007) Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet 369: 643–656.

4. GrayRH, KigoziG, SerwaddaD, MakumbiF, WatyaS, et al. (2007) Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet 369: 657–666.

5. WestercampN, BaileyRC (2006) Acceptability of male circumcision for prevention of HIV/AIDS in Sub-Saharan Africa: a review. AIDS Behav 11: 341–355.

6. NagelkerkeNJ, MosesS, de VlasSJ, BaileyRC (2007) Modelling the public health impact of male circumcision for HIV prevention in high prevalence areas in Africa. BMC Infect Dis 7: 16.

7. UNAIDS-WHO-SACEMA (2009) Expert group on modelling the impact and cost of male circumcision for HIV prevention: male circumcision for HIV prevention in high HIV prevalence settings: what can mathematical modelling contribute to informed decision making? PLoS Med 6: e1000109 doi:10.1371/journal.pmed.1000109

8. WhiteRG, GlynnJR, OrrothKK, FreemanEE, BakkerR, et al. (2008) Male circumcision for HIV prevention in sub-Saharan Africa: who, what and when? AIDS 22: 1841–1850.

9. WilliamsBG, Lloyd-SmithJO, GouwsE, HankinsC, GetzWM, et al. (2006) The potential impact of male circumcision on HIV in Sub-Saharan Africa. PLoS Med 3: e262 doi:10.1371/journal.pmed.0030262

10. AuvertB, MarseilleE, KorenrompEL, Lloyd-SmithJ, SittaR, et al. (2008) Estimating the resources needed and savings anticipated from roll-out of adult male circumcision in Sub-Saharan Africa. PLoS One 3: e2679 doi:10.1371/journal.pone.0002679

11. (2011) The 2010 National antenatal sentinel HIV and syphilis prevalence survey in South Africa. Department of Health, Pretoria, South Africa. 50–53 p.

12. LissoubaP, TaljaardD, RechD, DoyleS, ShabanguD, et al. (2010) A model for the roll-out of comprehensive adult male circumcision services in African low-income settings of high HIV incidence: the ANRS 12126 Bophelo Pele Project. PLoS Med 7: e1000309 doi:10.1371/journal.pmed.1000309

13. WHO-UNAIDS-JHPIEGO (2008) Manual for male circumcision under local anaesthesia. Version 2.5C. Geneva: WHO-UNAIDS.

14. UNAIDS (1998) Looking deeper into the HIV epidemic: a questionnaire for tracing sexual networks. In Best practice collection, Key materiel 98/27. Geneva: UNAIDS. 1–24.

15. JungBH, RezkNL, BridgesAS, CorbettAH, KashubaAD (2007) Simultaneous determination of 17 antiretroviral drugs in human plasma for quantitative analysis with liquid chromatography-tandem mass spectrometry. Biomed Chromatogr 21: 1095–1104.

16. JanssenRS, SattenGA, StramerSL, RawalBD, O'BrienTR, et al. (1998) New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes. JAMA 280: 42–48.

17. GuyR, GoldJ, CallejaJM, KimAA, ParekhB, et al. (2009) Accuracy of serological assays for detection of recent infection with HIV and estimation of population incidence: a systematic review. Lancet Infect Dis 9: 747–759.

18. ParekhBS, KennedyMS, DobbsT, PauCP, ByersR, et al. (2002) Quantitative detection of increasing HIV type 1 antibodies after seroconversion: a simple assay for detecting recent HIV infection and estimating incidence. AIDS Res Hum Retroviruses 18: 295–307.

19. FiammaA, LissoubaP, OliverA, SinghB, LaeyendeckerO, et al. (2010) Can HIV incidence testing be used for evaluating HIV intervention programs? A reanalysis of the Orange Farm male circumcision trial. BMC Infectious Diseases 10: 137.

20. McWalterTA, WelteA (2009) A comparison of biomarker based incidence estimators. PLoS One 4: e7368 doi:10.1371/journal.pone.0007368

21. McDougalJS, ParekhBS, PetersonML, BransonBM, DobbsT, et al. (2006) Comparison of HIV type 1 incidence observed during longitudinal follow-up with incidence estimated by cross-sectional analysis using the BED capture enzyme immunoassay. AIDS Res Hum Retroviruses 22: 945–952.

22. RosenbaumPR, RubinDB (1983) The central role of the propensity score in observational studies for causal effects. Biometrika 70: 41–55.

23. SatoT, MatsuyamaY (2003) Marginal structural models as a tool for standardization. Epidemiology 14: 680–686.

24. LissoubaP, TaljaardD, RechD, Dermaux-MsimangV, LegeaiC, et al. (2011) Adult male circumcision as an intervention against HIV: An operational study of uptake in a South African community (ANRS 12126). BMC Infect Dis 11: 253.

25. AgotKE, KiarieJN, NguyenHQ, OdhiamboJO, OnyangoTM, et al. (2007) Male circumcision in Siaya and Bondo Districts, Kenya: prospective cohort study to assess behavioral disinhibition following circumcision. J Acquir Immune Defic Syndr 44: 66–70.

26. MattsonCL, CampbellRT, BaileyRC, AgotK, Ndinya-AcholaJO, et al. (2008) Risk compensation is not associated with male circumcision in Kisumu, Kenya: a multi-faceted assessment of men enrolled in a randomized controlled trial. PLoS ONE 3: e2443 doi:10.1371/journal.pone.0002443

27. Ngwane Z (1997) Zulu. Bond G, editor. New-York: Rosen Publishing Group. pp. 38.

28. MahianeSG, LegeaiC, TaljaardD, LatoucheA, PurenA, et al. (2009) Transmission probabilities of HIV and herpes simplex virus type 2, effect of male circumcision and interaction: a longitudinal study in a township of South Africa. AIDS 23: 377–383.

29. AuvertB, Sobngwi-TambekouJ, CutlerE, NieuwoudtM, LissoubaP, et al. (2009) Effect of male circumcision on the prevalence of high-risk human papillomavirus in young men: Results of a randomized controlled trial conducted in Orange Farm, South Africa. J Infect Dis 199: 14–19.

30. TobianAA, SerwaddaD, QuinnTC, KigoziG, GravittPE, et al. (2009) Male circumcision for the prevention of HSV-2 and HPV infections and syphilis. N Engl J Med 360: 1298–1309.

31. WawerMJ, MakumbiF, KigoziG, SerwaddaD, WatyaS, et al. (2009) Circumcision in HIV-infected men and its effect on HIV transmission to female partners in Rakai, Uganda: a randomised controlled trial. Lancet 374: 229–237.

32. HallettTB, SinghK, SmithJA, WhiteRG, Abu-RaddadLJ, et al. (2008) Understanding the impact of male circumcision interventions on the spread of HIV in southern Africa. PLoS One 3: e2212 doi:10.1371/journal.pone.0002212